Development, Characterization and Anti-diabetic Investigation of Insulin-loaded Polymeric Composites Solid Dispersions for Enhanced Oral Delivery

Technical Summary: Development, Characterization, and Anti-diabetic Investigation of Insulin-loaded Polymeric Composites Solid Dispersions for Enhanced Oral Delivery

Problem Statement
Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune condition requiring lifelong exogenous insulin therapy. Currently, this therapy is administered parenterally (subcutaneously), a route associated with significant drawbacks including injection pain, allergic reactions, lipodystrophy, and poor patient compliance. While oral administration offers a non-invasive alternative, it faces substantial physiological barriers: insulin is a protein susceptible to rapid enzymatic degradation in the acidic gastric environment and proteolytic enzymes in the intestine, and it possesses poor intestinal permeability due to its high molecular weight and low lipophilicity. Consequently, oral bioavailability remains critically low (less than 2%), and no orally administered insulin product has yet achieved commercial approval.

Methodology
The study aimed to develop and characterize novel oral delivery systems using the solid dispersion technique to enhance insulin stability and bioavailability.

• Formulation: Two polymeric matrices were prepared using solvent evaporation. Matrix A consisted of a three-polymer blend (Soluplus®, Ethyl Cellulose [EC], and Hydroxypropyl Methylcellulose [HPMC]), while Matrix B utilized a two-polymer blend (Soluplus® and HPMC).
• Solid Dispersion Preparation: Eight batches (A1–A4 and B1–B4) were created by dispersing the polymeric films in ethanol and incorporating varying volumes of insulin (3, 5, or 10 mL). Batches A4 and B4 served as unloaded placebos. The formulations were dried via solvent evaporation and milled into granules.
• Characterization: The formulations underwent extensive physicochemical analysis, including micromeritic properties (angle of repose, bulk/tapped density, compressibility index, Hausner's ratio), encapsulation efficiency (EE), and drug loading capacity (LC). Structural and thermal properties were assessed via Fourier-transform infrared spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Scanning Electron Microscopy (SEM), and X-ray diffraction (XRD).
• In Vitro Release: Dissolution studies were conducted using a two-stage model: Simulated Gastric Fluid (SGF, pH 1.2) for 2 hours followed by Simulated Intestinal Fluid (SIF, pH 7.2) for 6 hours.
• In Vivo Evaluation: Anti-diabetic efficacy was evaluated in alloxan-induced diabetic mice (n=30). Groups were treated with various solid dispersion batches or commercial subcutaneous insulin. Blood glucose levels were monitored over 12 hours. Safety was assessed through hematological parameters (PCV, RBC, Hb) and biochemical markers for liver (ALT, AST, ALP) and kidney (Urea, Creatinine) function. Stability was monitored via pH measurements over three months.

Key Results

• Physicochemical Properties: All formulations exhibited excellent flow properties, with Hausner's ratios ranging from 1.02 to 1.07 and compressibility indices between 2.13% and 6.61%. Encapsulation efficiencies ranged from 54.21% to 78.69%, with Batch A1 showing the highest EE (78.69%) and loading capacity (48.17%).
• Structural Analysis: FTIR analysis confirmed the absence of chemical interactions between insulin and the polymers, indicating structural integrity was preserved. DSC and XRD results revealed a transition from crystalline to amorphous states in insulin-loaded batches, particularly in Batch B3, suggesting molecular dispersion within the polymer matrix which typically enhances dissolution. SEM imaging showed that insulin incorporation created surface porosity and irregularities, potentially facilitating drug release.
• In Vitro Release: Batch A2 (three-polymer blend) demonstrated the highest release in the gastric phase (80% within 80 minutes), while Batch B1 (two-polymer blend) showed significant release in the intestinal phase. The formulations exhibited sustained release characteristics, with peak release occurring between 90 and 100 minutes.
• In Vivo Efficacy: Oral administration of the solid dispersions resulted in significant reductions in blood glucose levels. Batch B3 (two-polymer blend) achieved the most pronounced hypoglycemic effect with a 79.26% reduction in blood glucose over 12 hours, outperforming the subcutaneous commercial insulin control (1.13% reduction in this specific study context) and other batches.
• Safety and Stability: Hematological studies indicated no significant toxicity in groups receiving active formulations. However, groups receiving formulations without insulin (F5) or specific batches (F3, F4) showed elevated liver enzymes, attributed to uncontrolled hyperglycemia or specific polymer-drug interactions. The formulations maintained stable pH levels over three months, suggesting potential for room temperature storage without cold chain dependence.

Significance and Claims
The paper claims that the developed insulin-loaded polymeric solid dispersions represent a promising alternative to conventional injection therapies. The study highlights that:

1. Enhanced Bioavailability: The solid dispersion technology successfully protected insulin from degradation in the simulated gastric environment and facilitated sustained release in the intestinal tract.
2. Therapeutic Efficacy: The formulations, particularly the Soluplus® and HPMC blend (Batch B3), demonstrated superior glycemic control in diabetic mice compared to subcutaneous injection in the context of this specific study, offering a viable path toward non-invasive diabetes management.
3. Safety and Stability: The formulations exhibited a favorable safety profile regarding hematological parameters and showed chemical stability over a three-month period, potentially addressing the storage limitations of parenteral insulin.
4. Future Potential: The authors conclude that these findings support the potential of polymer-based oral insulin formulations to improve patient compliance and quality of life, though they note that further pharmacokinetic studies and clinical trials are required to confirm these benefits for clinical translation.